Lessons from immuno-oncology: a new era for cancer nanomedicine?

Article metrics

Abstract

Despite a decade of intensive preclinical research, the translation of cancer nanomedicine to the clinic has been slow. Here, we discuss how recent lessons learned from the successes with immuno-oncology therapies could be applied to cancer nanomedicine and how this may help to overcome some of the key technical challenges in this field.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Shi, J., Kantoff, P. W., Wooster, R. & Farokhzad, O. C. Cancer nanomedicine: progress, challenges and opportunities. Nat. Rev. Cancer 17, 20–37 (2017).

  2. 2

    Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016).

  3. 3

    Lammers, T. et al. Cancer nanomedicine: is targeting our target? Nat. Rev. Mater. 1, 16076 (2016).

  4. 4

    Jiang, W. et al. Designing nanomedicine for immuno-oncology. Nat. Biomed. Eng. 0029 (2017).

  5. 5

    Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defense for cancer immunotherapy. Nature 534, 396–401 (2016).

Download references

Author information

Correspondence to Wen Jiang or Betty Y. S. Kim.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jiang, W., Yuan, H., Chan, C. et al. Lessons from immuno-oncology: a new era for cancer nanomedicine?. Nat Rev Drug Discov 16, 369–370 (2017) doi:10.1038/nrd.2017.34

Download citation

Further reading